12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Trobalt retigabine regulatory update

EMA's CHMP recommended restricting the use of seizure drug Trobalt retigabine from GlaxoSmithKline to last-line therapy in patients with partial epilepsy due to the risk of retinal pigmentation. CHMP, which said the benefit-risk balance for Trobalt "remains positive" in patients for whom other anti-epileptic medicines...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >